Risk factors for anemia after one year of kidney transplantation

Ismael Quezada Adame1, Ramón Espinoza Pérez2, José Cruz Santiago3, María de la Luz Sevilla González4, Rodolfo Rivas Ruiz5, Genaro Ángel Cuazochpa Delgadillo6, Blanca Estela Herrera Morales7, Ana Yadira Bermúdez González8, Efrain Absalon Medina Villasenor9 and Juan Carlos H Hernández Rivera10

1Hospital coordination of organ and tissue donation for transplantation purposes. Regional General Hospital 196, Mexican Institute of Social Security, Ecatepec, State of Mexico, Mexico
2Renal Transplant Unit, National Medical Center “XXI Century”, Mexican Institute of Social Security, Mexico City, Mexico
3Renal Transplant Unit, National Medical Center Specialties Hospital “La Raza”, Mexican Institute of Social Security, Mexico City, Mexico
4Section of Postgraduate Studies and Research. National Polytechnic Institute, Mexico City, Mexico
5Clinical Research Training Center (CAIC), Health Research Coordination, National Medical Center “XXI Century”, Mexican Institute of Social Security, Mexico City, Mexico
6Hospital General Regional Hospital 196 “Fidel Velázquez Sánchez”, Mexican Institute of Social Security, Ecatepec, State of Mexico, Mexico
7Betania Medical Specialties, Los Reyes Acaquilpan, State of Mexico, Mexico
8Unit of Medical Research in Nephrological Diseases, National Medical Center Specialties Hospital “XXI Century”, Mexican Institute of Social Security, Mexico City, Mexico
9Clinical Research Training Center (CAIC), Health Research Coordination, National Medical Center “XXI Century”, Mexican Institute of Social Security, Mexico City, Mexico
10*Correspondence to: Juan Carlos H Hernández Rivera, Hernández RJCH, Av. Cuauhtémoc 330, Colonia Doctores, México, DF, CP 06722, Tel: 5559664384; E-mail: juancarloshernandezrivera@hotmail.com

Abstract
Post renal transplant anemia (PTA) occurs in one out of every four patients and, by itself, increases mortality by six times at 10 years. The risk factors associated with its presence, during the first year, have been reported in some investigations with populations, generally different from Latin America. Therefore, a retrospective, longitudinal study was carried out that included 1,438 kidney transplant patients over six years in two public Medical Centers in Mexico. There were 39 deaths (2.7%) and 44 graft losses (3.1%) before one year of follow-up, who left the study. In the 1,355 cases that continued, a prevalence of anemia of 15.5% (n = 210) was found at 12 months. In the bivariate analysis with the PTA at one year, the cadaveric origin of the graft resulted in an OR of 2.24, 95% CI (1.65-3.05) and for creatinine (Cr) > 2.0mg / dL at 6 months, OR of 4.18, 95% CI (2.66-6.56). With Cr > 2.0mg / dL; At 12 months, an OR of 5.55 was obtained, 95% CI (3.66-8.42). Height, baseline Cr, as well as female sex, had a statistically significant relationship with the outcome. In the multivariate model performed, the cadaveric donor, the female sex, and the Cr > 2.0mg / dL at 6 and 12 months predicted anemia at one year. It is concluded that Cr > 2.0 mg / dL, the female sex and the cadaveric graft are the main risk factors for anemia, one year after kidney transplantation.

Abbreviations: PTA: Post renal transplant anemia; Cr: Creatinine; Hb: Hemoglobin; KT: Kidney Transplantation; EPO: Erythropoietin; ACEIs: Angiotensin converting enzyme inhibitors; ARA II: Angiotensin II receptor antagonists; BMI: Body mass index; GFR: glomerular filtration rate

Introduction
Compared with other replacement therapies, kidney transplantation (KT) has offered the best results in the patient's living condition and survival [1-4], however, it is not without complications. One of them is anemia, which is usually present in patients with advanced stages of kidney damage. This condition is correctable, in most cases, with KT, however, when it is not achieved, it negatively influences the function, conservation and survival of the kidney graft [5-14] due to its effect at the cardiovascular level.

The prevalence of post renal transplant anemia (PTA) is 80% in the first month after surgery, reducing to 20% in the first year [15,16].

The causes include age, sex, type of donor (living or cadaveric), surgical bleeding, hemodilution, lack of erythropoietin (EPO) production, iron or folate deficiency, parvovirus infections; neoplasms, hypoalbuminemia, use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor antagonists (ARA II); inflammatory processes secondary to autoimmune diseases, antibodies against erythropoietin (alpha and beta); immunosuppressants, antibiotics, antivirals, and immunoglobulin treatment [17-22]. Likewise, serum creatinine values above 2mg / dL decrease the erythropoietin produced by the transplanted kidney, as well as its effect on the pro-erythroblast, promoting the persistence of anemia [23,24]. It should be noted that, in studies with analysis adjusted to age, gender and stage of kidney disease, an increase in the risk of mortality was observed with moderate (HR 6.16, 95% CI 1.12-34.33, p = 0.038) and severe (HR 9.79, 95% CI 2.57-37.26, p = 0.001) [25], after 10 years of follow-up.

*Correspondence to: Juan Carlos H Hernández Rivera, Hernández RJCH, Av. Cuauhtémoc 330, Colonia Doctores, México, DF, CP 06722, Tel: 5559664384; E-mail: juancarloshernandezrivera@hotmail.com

Key words: anemia, kidney transplant, risk factors

Received: March 24, 2021; Accepted: March 29, 2021; Published: April 01, 2021
Considering that in Latin America there are few publications in this regard, the present study was carried out in order to identify risk factors for PTA, at one year in a Mexican population.

Methods

This is a retrospective, longitudinal study, carried out in the transplant units of two public Medical Centers, of the Mexican Institute of Social Security (IMSS), from January 2013 to January 2019. All transplant patients were included in the period established, excluding those who did not have complete data on the variables under study. Those who did not complete the one-year follow-up due to death or graft loss were eliminated.

The data was obtained from electronic medical records, on institutional virtual platforms. The main outcome was anemia at one year of follow-up after transplantation, presented as a dichotomous variable. Among the variables considered in the baseline analysis, anemia prior to transplantation was categorized as: absent, mild and severe. Similarly, replacement therapy prior to graft, as a polytomous variable, was divided into: anticipated, when there was no replacement therapy, dialysis (peritoneal) and hemodialysis.

Kolmogorov-Smirnov normality tests were applied to all the variables considered, applying the relevant test for each one: Pearson, Spearman and Chi-square; Correlation was sought and OR with 95% CI was calculated. For the multivariate analysis, a logistic regression model was developed with all the variables, leaving in the final model those that had the greatest statistical significance in the bivariate. In all the tests carried out, a value of p. less than 0.05, was considered for bilateral significance.

The study was accepted by the IMSS National Research Ethics Committee, considering it a risk-free study.

Results and Discussion

From the universe, made up of 1608 subjects, 170 were excluded, with incomplete data, leaving 1438 cases, in whom the characteristics and secondary outcomes were analyzed (Table 1), finding, before completing one year of follow-up, 39 deaths (2.7%) and 44 graft losses (3.1%), which were eliminated from the study.

In the population that presented the main outcome (N = 1355), comparing the groups with and without anemia, at one year of follow-up, an OR of 2.24 was found for the cadaveric donor, 95% CI (1.65-3.05). Creatinine above 2.0mg / dL, at 6 months, had OR of 4.18, 95% CI (3.66-8.42) (Figure 1). The rest of the results are shown in Table 2.

When developing a regression model in which the variables with statistical significance were included in the bivariate, the type of donor, sex, as well as creatinine at six and twelve months were taken for a final model (dichotomous with cut-off at 2.0 mg / dL.), (Table 3).

We found that the factors associated with PTA at one year of follow-up were: height, baseline creatinine, creatinine at the third, sixth and twelfth month; increasing the risk for women, cadaveric donor, serum creatinine above 1.2 mg/dL at the sixth and twelfth month, as well as creatinine above 2.0 mg/dL at the third, sixth and twelfth month. The cadaveric donor, female sex, and creatinine above 2.0mg/dL, at six and 12 months, were distinguished as predictors of PTA, as a whole.

Mortality and graft loss, as secondary outcomes before one year of post-transplant follow-up, occurred in 2.7% and 3.1%, respectively.

| Characteristic                      | Participants Included | N=1438 |
|-------------------------------------|-----------------------|--------|
| Hospital                            |                       |        |
| 1                                   | 832 (57.9) ^          |        |
| 2                                   | 606 (42.1) ^          |        |
| Sex                                 |                       |        |
| Female                              | 603 (41.9) ^          |        |
| Male                                | 835 (58.1) ^          |        |
| Donor                               |                       |        |
| Cadaveric                           | 383 (26.6) ^          |        |
| Living                              | 1055 (73.4) ^         |        |
| Retransplant                        | 47 (3.3) ^            |        |

Table 1. Characteristics of kidney transplant population

| Characteristic                      | Anemia per year 210 (15.5) | P | OR (IC 95%) |
|-------------------------------------|-----------------------------|---|-------------|
| Sex                                 |                             |   |             |
| Female                              | 103 (7.6) ^                 | 0.01^ | 0.70 (0.52-0.94) |
| Male                                | 107 (7.9) ^                 |    |             |
| Donor                               |                             |   |             |
| Cadaveric                           | 85 (6.3) ^ 125 (9.2) ^      | 0 ^ | 2.24 (1.65-3.05) |
| Living                              | 31 (25, 42) ^              | 0.37 ^ | Does not apply |
| Age, in years                       | 23.7 (20.9, 26.2) ^        | 0.74 ^ | Does not apply |
| Body mass index                     |                             |   |             |
| Basal creatinine in milligrams/deciliter | 10.7 (7.8, 13) ^ 30 (2.2) ^ 27 (2) ^ 153 (11.3) ^ | 0.03 ^ | Does not apply |

Some authors have reported slightly higher prevalence in populations other than ours (Spanish and North American). Such is the case of the publications by Hernández [26], El-Husseini [27] and Hirata [28], who found 3% to 4% for mortality and 7% to 8% for graft loss.
Adame IQ (2021) Risk factors for anemia after one year of kidney transplantation

Table 3. Logistic regression to predict anemia one year after kidney transplantation*

| Variable | B** | p   | OR  | IC95% |
|----------|-----|-----|-----|-------|
| Creatinine twelfth month dichotomous 2.0 milligrams/deciliter | 1.45 | 0 | 4.26 | 2.61-6.94 |
| Creatinine sixth month dichotomous 2.0 milligrams/deciliter | 0.72 | 0.01 | 2.05 | 1.19-3.55 |
| Cadaveric Donor | 0.74 | 0 | 2.09 | 1.52-2.88 |
| Sex (Female) | 0.5 | 0.002 | 1.65 | 1.2-2.26 |

* Global model explanation percentage of 84.5%, with Nagelkerke's R2 of 0.11
** Beta coefficient

However, the data observed by Hol y cols. [29], reached up to 11% mortality, depending on the type of donor (living or cadaveric), studying 500 cases, within a third level public concentration hospital, in Mexico. They also found 11 to 21% graft loss in the same period of time and, although the variables related to these outcomes were not analyzed in the present study, our prevalence was three times lower for mortality and seven times lower for loss of kidney graft.

This contrast, despite the similarities between the type of population included in both investigations, has no clear explanation. The same happens when comparing the results with Gondos [2], who in a multicenter collaborative study in Europe and the United States, when dividing the groups by ethnic origin, found, in more than 5,300 Hispanic Americans, a prevalence of 8.5% of loss of kidney graft, a year.

Perhaps, the selection of recipients, as well as the experience in the management and follow-up of patients within the transplant Units, may be factors to consider.

Regarding the presence of anemia, one year after transplantation, a 15.5% prevalence was found, a lower figure than that reported by Petrone [30] in Argentina (42%), Huang (21%) [13], Imoagene [31], and Turkowski (20%) [22], but slightly higher than that described by Rosales (12.9%) [32] in Mexico.

Petrone [30] found a significant difference when comparing anemia at one year, by sex, age and serum creatinine (dichotomous), however, only pediatric age and values above 2.0mg d/L were significant in its logistic regression. Their study does not specify pediatric age ranges, so it is unknown whether the values are different from ours, where there were no subjects under 16 years of age, a difference that could explain the lack of association between age and anemia in our case. On the other hand, in the bivariate analysis, there is agreement in our calculations of significance for sex and serum creatinine above 2.0mg. The latter was also one of the significant variables in the logistic regression of both studies.

By dividing the groups by ethnic origin, found, in more than 5,300 Hispanic Americans, a prevalence of 8.5% of loss of kidney graft, a year.

Imoagene [31], in the United States, indicated as a protective factor for anemia at one year, the male sex (OR 0.4, CI95% 0.2-0.6), data that agrees with the risk that we identified for the female sex (OR 1.42, CI95 % 1.05-1.91). Similar results were published by Mix [33] (OR 3.61 with 95% CI 1.60-8.15) and other authors [33-36], including a recent article by Cruz-Santiago y cols. [37], within one of the hospitals that participated in our study. When comparing the median age with those of several studies [5,10,13,15,16,31,38,39], it is up to 18 years younger, which is probably due to the fact that in our country there is a high incidence of chronic degenerative pathologies in young adults, leading to end-stage renal failure at an early age. Thus, in our analysis, no association was found between age and anemia, unlike Huang [13], who, including only patients with a living donor transplant, reported a protective effect at older age, with a HR 0.98 e 95% CI from 0.95 to 1.00, in a group that did not exceed the age of 55 years.

In the rest of the variables, it is not possible to explain the difference of our results with those of other publications.

This is one of the few studies, in search of risk factors for post-kidney transplant anemia, carried out in Latin America, which implies obtaining new data that strengthen the documented evidence for this condition. Furthermore, by addressing the sociodemographic characteristics of a population typical of the region, different from most previous publications, it allows making comparisons in this regard. On the other hand, it joins a short list of investigations that specifically analyze PTA during the first year. Most of the studies that have investigated the persistence of this post-renal transplant pathology have carried out a general analysis on a longer time line and without focusing on the first months of late PTA.

Our study can be considered numerous, based on the subjects included, compared to several investigations in which one or two hospital centers have participated. This can be explained by the fact that the Units where the recruitment was carried out are public concentration hospitals, in addition to the fact that the total population was considered for 5 years. This represents a strength, as selection bias was avoided.

Study limitations

Among the limitations of our research, in addition to the fact that it was a retrospective and descriptive study, is the failure to include significant variables in the analysis in other reports, such as immunosuppressive treatment [10,16,22,31,38,39], comorbidities [12-17,31], intraoperative bleeding [16,40], cold ischemia time, delayed graft function [22,40], drug interaction [38] and treatment of anemia [10,17,19,22,38,39]; furthermore, the follow-up was relatively short for late PTA, compared with existing articles, where subjects have been observed for longer periods [10,12,14,38,39], reaching up to more than 10 years [8].

Conclusion

Height, pre-transplant creatinine, as well as creatinine at the third, sixth and twelfth month are associated with the presence of anemia one year after kidney transplantation, in addition, there is a greater risk in women, in those who receive the organ of cadaveric origin and in presence of serum creatinine above 2.0 mg/dL after transplantation, during the first year.

It is convenient to carry out investigations where the limitations of the present study are solved, in order to corroborate the results obtained, since, although some variables studied coincide with what was
previously published, others differ notably. This could be achieved with methodological designs that include a greater number of variables that influence the outcome, multicenter studies, and follow-ups for longer periods of time. On the other hand, the study of factors associated with mortality and graft loss in this type of patient can be a line of research to be developed, in a complementary way.

Acknowledgement
To the Mexican Institute of Social Security, to the Renal Transplant Units of the National Medical Center XXI Century and the National Medical Center Specialties Hospital “La Raza”, the IMSS Clinical Research Training Center. To our collaborators. To our families. A special thanks to all transplant patients in our Institution, to whom we owe ourselves professionally.

Conflict of interests
The authors of this article declare that they have no conflict of interest in the results obtained.

Financing
The present study was developed without funding from any institution. The resources used were provided by the authors.

References
1. Martín P, Ernst P (2006) Transplante renal. Kidney transplant. An Sist Sanit Navar 29: 79-92. [Crossref]
2. Adam G, Döhler B, Brenner H, Opelz G (2013) Kidney Graft Survival in Europe and the United States: Strikingly Different Long-Term Outcomes, Transplantation 95: 267-274 [Crossref]
3. Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, et al. (2011) Systematic review: Kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant 11: 2093-2109. [Crossref]
4. Purnell TS, Auguste P, Crews DC, Lamprea-Montealegre J, Olufade T, et al. (2013) Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 17: 889-899. [Crossref]
5. Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, et al. (2006) Anemia and mortality and graft loss in this type of patient can be a line of research to be developed, in a complementary way.

Conflict of interests
The authors of this article declare that they have no conflict of interest in the results obtained.

Financing
The present study was developed without funding from any institution. The resources used were provided by the authors.

References
1. Martín P, Ernst P (2006) Transplante renal. Kidney transplant. An Sist Sanit Navar 29: 79-92. [Crossref]
2. Adam G, Döhler B, Brenner H, Opelz G (2013) Kidney Graft Survival in Europe and the United States: Strikingly Different Long-Term Outcomes, Transplantation 95: 267-274 [Crossref]
3. Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, et al. (2011) Systematic review: Kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant 11: 2093-2109. [Crossref]
4. Purnell TS, Auguste P, Crews DC, Lamprea-Montealegre J, Olufade T, et al. (2013) Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 17: 889-899. [Crossref]
5. Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, et al. (2006) Anemia and mortality and graft loss in this type of patient can be a line of research to be developed, in a complementary way.

Conflict of interests
The authors of this article declare that they have no conflict of interest in the results obtained.

Financing
The present study was developed without funding from any institution. The resources used were provided by the authors.

References
1. Martín P, Ernst P (2006) Transplante renal. Kidney transplant. An Sist Sanit Navar 29: 79-92. [Crossref]
2. Adam G, Döhler B, Brenner H, Opelz G (2013) Kidney Graft Survival in Europe and the United States: Strikingly Different Long-Term Outcomes, Transplantation 95: 267-274 [Crossref]
3. Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, et al. (2011) Systematic review: Kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant 11: 2093-2109. [Crossref]
4. Purnell TS, Auguste P, Crews DC, Lamprea-Montealegre J, Olufade T, et al. (2013) Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 17: 889-899. [Crossref]
5. Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, et al. (2006) Anemia and mortality and graft loss in this type of patient can be a line of research to be developed, in a complementary way.

Conflict of interests
The authors of this article declare that they have no conflict of interest in the results obtained.

Financing
The present study was developed without funding from any institution. The resources used were provided by the authors.

References
1. Martín P, Ernst P (2006) Transplante renal. Kidney transplant. An Sist Sanit Navar 29: 79-92. [Crossref]
2. Adam G, Döhler B, Brenner H, Opelz G (2013) Kidney Graft Survival in Europe and the United States: Strikingly Different Long-Term Outcomes, Transplantation 95: 267-274 [Crossref]
3. Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, et al. (2011) Systematic review: Kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant 11: 2093-2109. [Crossref]
4. Purnell TS, Auguste P, Crews DC, Lamprea-Montealegre J, Olufade T, et al. (2013) Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 17: 889-899. [Crossref]
5. Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, et al. (2006) Anemia and mortality and graft loss in this type of patient can be a line of research to be developed, in a complementary way.

Conflict of interests
The authors of this article declare that they have no conflict of interest in the results obtained.

Financing
The present study was developed without funding from any institution. The resources used were provided by the authors.
37. Cruz-Santiago J, Velázquez-Zambrano C, Escamilla-Galindo PA, Díaz-Rosas G, Rojas-Rodríguez FO, et al. (2020) Change in the Pattern of Posttransplantation Anemia in Kidney Receptors: Sex Role in Recipients and Type of Donor. Transplant Proc 52: 1163-1168. [Crossref]

38. Vanrenterghem Y, Ponticelli C, Morales JM, Abramowicz D, Baboolal K, et al. (2003) Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant 3: 835-845. [Crossref]

39. Yorgin PD, Scandling JD, Belson A, Sanchez J, Alexander SR, et al. (2002) Late post-transplant anemia in adult renal transplant recipients. An under-recognized problem? Am J Transplant 2: 429-435. [Crossref]

40. Tsuchimoto A, Masutani K, Haruyama N, Nagata M, Noguchi H, et al. (2013) Renal interstitial fibrosis in 0-hour biopsy as a predictor of post-transplant anemia. Am J Nephrol 38: 267 [Crossref]